These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30810585)

  • 1. Why are biosimilars much more complex than generics?
    Pagani E
    Einstein (Sao Paulo); 2019 Feb; 17(1):eED4836. PubMed ID: 30810585
    [No Abstract]   [Full Text] [Related]  

  • 2. Current Japanese Regulatory Systems for Generics and Biosimilars.
    Kuribayashi R; Sawanobori K
    J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics?
    Oza B; Radhakrishna S; Pipalava P; Jose V
    J Postgrad Med; 2019; 65(4):227-232. PubMed ID: 31571620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hot Topics in Primary Care: Demystifying the Differences: Follow-on Biologics, Biosimilars, and Generics.
    Wright EE; Blevins TC; Reed B; Pollom RD
    J Fam Pract; 2017 Apr; 66(4 Suppl):S22-S27. PubMed ID: 28375404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fractal geometry as a new approach for proving nanosimilarity: a reflection note.
    Demetzos C; Pippa N
    Int J Pharm; 2015 Apr; 483(1-2):1-5. PubMed ID: 25659328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BIOSIMILAR DRUGS ARE NOT GENERICS.
    Zangeneh F; Dolinar R
    Endocr Pract; 2016 Jan; 22(1):6-7. PubMed ID: 26731083
    [No Abstract]   [Full Text] [Related]  

  • 7. On safety margin for drug interchangeability.
    Zheng J; Chow SC; Song F
    J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective.
    Sharma A; Kumar N; Kuppermann BD; Bandello F; Loewenstein A
    Br J Ophthalmol; 2020 Jan; 104(1):2-7. PubMed ID: 31315829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What are biosimilars and are they important?
    Drug Ther Bull; 2013 May; 51(5):57-60. PubMed ID: 23657197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
    Gonçalves J; Araújo F; Cutolo M; Fonseca JE
    Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations.
    Dranitsaris G; Amir E; Dorward K
    Drugs; 2011 Aug; 71(12):1527-36. PubMed ID: 21861538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comprehensive Overview on Biosimilars.
    Kadam V; Bagde S; Karpe M; Kadam V
    Curr Protein Pept Sci; 2016; 17(8):756-761. PubMed ID: 26916165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulary Considerations for Insulins Approved Through the 505(b)(2) "Follow-on" Pathway.
    Rasmussen JT; Ipema HJ
    Ann Pharmacother; 2019 Feb; 53(2):204-210. PubMed ID: 30122087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilar insulins: a European perspective.
    DeVries JH; Gough SC; Kiljanski J; Heinemann L
    Diabetes Obes Metab; 2015 May; 17(5):445-51. PubMed ID: 25376600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights of biosimilars through SWOT analysis.
    Patel MM; Shah PJ; Patel BM
    Expert Opin Biol Ther; 2014 Feb; 14(2):139-44. PubMed ID: 24151903
    [No Abstract]   [Full Text] [Related]  

  • 16. [Biosimilars : Current state of the build up to series production].
    Aringer M; Dörner T
    Z Rheumatol; 2013 Nov; 72(9):873-7. PubMed ID: 23934050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
    Falit BP; Singh SC; Brennan TA
    Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Challenging Future of the Biosimilars Market.
    Joseph E
    J Pharm Pract; 2016 Jun; 29(3):266-7. PubMed ID: 27169735
    [No Abstract]   [Full Text] [Related]  

  • 19. Biosimilar drugs : concerns and opportunities.
    Genazzani AA; Biggio G; Caputi AP; Del Tacca M; Drago F; Fantozzi R; Canonico PL
    BioDrugs; 2007; 21(6):351-6. PubMed ID: 18020619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generics, chemisimilars and biosimilars: is clinical testing fit for purpose?
    Warren JB
    Br J Clin Pharmacol; 2013 Jan; 75(1):7-14. PubMed ID: 22574725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.